Abstract
In this paper the modelling objective is to determine the drug alternation time which minimises the formation of resistant tumour cells when delivering two non-cross resistant chemotherapeutics given such drugs cannot be delivered simultaneously and constraints due to pharmacokinetics and protocol rest phases. We initially consider cell cycle phase non-specific models, as investigated by Goldie and Coldman. By extending previous work, these models are generalised to consider chemotherapeutic S-phase specificity.
We find with the cell cycle phase non-specific models that once the alternation time of the drugs is reduced below a critical threshold, a substantial improvement in protocol outcome is predicted. Extensive improvements are also observed for the S-phase specific investigation if the drugs can be alternated extremely rapidly. However, this is typically impossible due to pharmacokinetic constraints. Under such circumstances, the most appropriate choice of the alternation time can depend sensitively on the median and variance of the tumour cell cycle time in a complicated manner. For schedulings motivated by Capecitabine protocols, we find that switching the drugs only once, or at most twice, between rest phases gives the most reliable alternation time.
The main and novel conclusion of this paper is the modelling prediction that one must be much more specific in the choice of the protocol alternation time if attempting to observe the improvements promised by Goldie and Coldman’s alternation hypothesis for the rest phases, pharmacokinetics and delivery mechanisms typically encountered in cell cycle phase specific chemotherapy protocols.
Similar content being viewed by others
References
Adam, R., 2004. Current surgical strategies for the treatment of colorectal cancer liver metastases. Eur. J. Cancer Suppl. 2, 21–26.
Agur, Z., 1998. Resonance and anti-resonance in the design of chemotherapeutic protocols. J. Theor. Med. 1, 237–245.
Agur, Z., Dvir, Y., 1994. Use of knowledge on ϕ n series for predicting optimal chemotherapy treatment. Random Comput. Dyn. 2, 279–286.
Agur, Z., Arnon, R., Schechter, B., 1988. Reduction of cytotoxicity to normal tissues by new regimens of phase-specific drugs. Math. Biosci. 92, 1–15.
Agur, Z., Arnon, R., Schechter, B., 1992. Effect of the dosing interval on survival and myelotoxicity in mice treated by Cytosine arabinoside. Eur. J. Cancer 28A, 1085–1090.
Agur, Z., Arnon, R., Sandak, B., Schechter, B., 1991. Zidovudine toxicity to murine bone marrow may be affected by the exact frequency of drug administration. Exp. Hematol. 19, 364–368.
Anderson, L.K., Mackey, M.C., 2001. Resonance in periodic chemotherapy: a case study of acute myelogenous leukaemia. J. Theor. Biol. 209, 113–130.
Andreeff, M., Goodrich, D.W., Pardee, A.B., 2000. Cell proliferation, differentiation, and apoptosis. In: Holland, J.F., Kufe, D.W., Pollack, R.E., Weichselsbaum, R.R., Frei, E.I., Bast, R.C. (Eds.), Holland-Frei Cancer Medicine. Decker Inc. (Chapter 2).
Belpomme, D., 1991. Diversity of the resistance mechanisms to anticancer cytotoxic drugs. M S-Medecine Sciences 7, 465–472.
Brockmann, 1976. The Pharmacological Basis of Cancer Chemotherapy. Williams and Wilkins Publishers, Baltimore, pp. 692–710.
Bruce, W.R., Meaker, B.E., Valeriote, F.A., 1966. Comparison of normal hemapoietic and transplanted lymphoma colony forming cells to chemotherapeutic agents administered in vivo. J. Nat. Cancer Inst. 37, 233–245.
Buzzoni, R., Bonadonna, G., Valagussa, P., Zambetti, M., 1991. Adjuvant chemotherapy with doxorubicin plus cyclophosphamide, methotrexate, and fluorouracil in the treatment of resectable breast cancer with more than three positive axillary nodes. J. Clin. Oncol. 9, 2134–2140.
Chiorino, G., Metz, J.A.J., Tomasoni, D., Ubezio, P., 2001. Desynchronisation rate in cell populations: mathematical modelling and experimental data. J. Theor. Biol. 208, 185–199.
Cojocaru, L., Agur, Z., 1992. Theoretical analysis of interval drug dosing for cell-cycle-phase-specific drugs. Math. Biosci. 109, 85–97.
Coldman, A.J., Goldie, J.H., 1983. A model for the resistance of tumour cells to cancer chemotherapeutic agents. Math. Biosci. 65, 291–307.
Coldman, A.J., Goldie, J.H., 1998. Drug resistance in cancer: mechanisms and models. CUP.
Coldman, A.J., Murray, J.M., 2000. Optimal control for a stochastic model of cancer chemotherapy. Math. Biosci. 168, 187–200.
Day, R.S., 1986. Treatment sequencing, asymmetry and uncertainty: protocol strategies for combination chemotherapy. Cancer Res. 46, 3876–3885.
Deplacido, S. et al., 1995. CMF vs alternating CMF/EV in the adjuvant treatment of operable breast-cancer—a single-center randomized clinical-trial (naples gun-3 study). Br. J. Cancer 71, 1283–1287.
Dibrov, B.F., 1998. Resonance effect in self renewing tissues. J. Theor. Biol. 192, 15–33.
Dibrov, B.F., Zhabotinsky, A.M., Neyfakh, Y.A., Orlova, M.P., Churikova, L.I., 1985. Mathematical model of cancer chemotherapy. Periodic schedules of phase-specific cytotoxic-agent administration increasing the selectivity of therapy. Math. Biosci. 73, 1–31.
Dube, S., Heyen, F., Jenicek, M., 1997. Adjuvant chemotherapy in colorectal cancer. Dis. Colon Rectum 40, 35–41.
Frei, E.I., Antman, K.H., 2000. Principles of dose, schedule, and combination chemotherapy. In: Holland, J.F., Kufe, D.W., Pollack, R.E., Weichselsbaum, R.R., Frei, E.I., Bast, R.C. (Eds.), Holland-Frei Cancer Medicine. Decker Inc. (Chapter 40).
Gaffney, E.A., 2004. The application of mathematical modelling to aspects of adjuvant chemotherapy scheduling. J. Math. Biol. 48, 375–422.
Gilewski, T.A., Dang, C., Surbone, A., Norton, L., 2000. Cytokinetics. In: Holland, J.F., Kufe, D.W., Pollack, R.E., Weichselsbaum, R.R., Frei, E.I., Bast, R.C. (Eds.), Holland-Frei Cancer Medicine. Decker Inc. (Chapter 38).
Goldie, J.H., Coldman, A.J., 1983. Quantitative model for multiple levels of drug resistance in clinical tumours. Cancer Treat. Rep. 67, 923–931.
Goldie, J.H., Coldman, A.J., 1986. Application of theoretical models to chemotherapy protocol design. Cancer Treat. Rep. 70, 127–131.
Goldie, J.H., Coldman, A.J., Gudaskas, G.A., 1982. Rationale for the use of alternating non-cross resistant chemotherapy. Cancer Treat. Rep. 66, 439–449.
Guichard, S., Hennebelle, I., Bugat, R., Canal, P., 1998. Cellular interactions of 5-fluorouracil and the camptothecin analogue CPT-11 (irinotecan) in a human colorectal carcinoma cell line. Biochem. Pharmacol. 55, 667–676.
Harnevo, L.H., Agur, Z., 1992. Drug resistance as a dynamic process in a model for multi-step gene amplification under various levels of selection stringency. Cancer Chemother. Pharmacol. 30, 469–476.
Ishikawa, T., Utoh, M., Sawada, N., Nishida, M., Fukase, Y., Sekiguchi, F., Ishitsuka, H., 1998. Tumor selective delivery of 5-fluorouracil by capecitabine, a new oral fluoropyrimidine carbamate in human cancer xenografts. Biochem. Pharmacol. 55, 1091–1097.
Kemeny, N., Huang, Y., Cohen, A.M., Shi, W., Conti, J.A. et al., 1999. Hepatic arterial infusion of chemotherapy after resection of hepatic metastases. New England J. Med. 341, 2039–2048.
Mader, R.M., Muller, M., Steger, G.G., 1998. Resistance to 5-fluorouracil. Gen. Pharmacol. 31, 661–666.
Midgley, R., Kerr, D.J., 1999. Seminar in colorectal cancer. Lancet 353, 391–399.
Midgley, R., Kerr, D.J., 2000. ABC of colorectal cancer: adjuvant chemotherapy. BMJ 321, 1208–1211.
Morton, K.W., Mayers, D.F., 1994. Numerical Solution Of Partial Differential Equations. Cambridge University Press.
Murray, J.M., 1997. The optimal scheduling of two drugs with simple resistance for a problem in cancer chemotherapy. IMA J. Math. Appl. Med. Biol. 14, 283–303.
Nicum, S., Midgley, R., Kerr, D.J., 2000. Chemotherapy for colorectal cancer. J. R. Soc. Med. 93, 416–419.
Ojima, I., Ferlini, C., 2003. New insights into drug resistance in cancer. Chem. Biol. 10, 583–589.
Rew, D.A., Wilson, G.D., 2000. Cell production rates in human tissues and tumours and their significance. Part II: clinical data. Eur. J. Surg. Oncol. 26, 405–417.
Shochat, E., Hart, D., Agur, Z., 1999. Using computer simulations for evaluating the efficacy of breast cancer chemotherapy protocols. J. Math. Models Methods Appl. Sci. 9, 599–615.
Spielmann, M., Tubiana-Hulin, M., Namer, M., Mansouri, H., Bougnoux, P., Tubiana-Mathieu, N., Lotz, V., Eymard, J.C., 2002. Sequential or alternating administration of docetaxel (taxotere) combined with FEC in metastatic breast cancer: a randomised phase II trial. Br. J. Cancer 85, 692–697.
Stangl, R., Altendorf-Hofmann, A., Charnley, R.M., Scheele, J., 1994. Factors influencing the natural history of colorectal liver metastases. Lancet 343, 1405–1410.
Takahashi, T., Bhide, P.G., Goto, T., Miyama, S., Caviness Jr, V.S., 1999. Proliferative behavior of the murine cerebral wall in tissue culture: cell cycle kinetics and checkpoints. Exp. Neurol. 156, 407–417.
Tebbutt, N.C., Cattell, E., Midgley, R., Cunningham, D., Kerr, D.J., 2002. Systemic treatment of colorectal cancer. Eur. J. Cancer 38, 1000–1015.
Tsurutani, J., Nitta, T., Hirashima, T., Komiya, T., Uejima, H., Tada, H., Syunichi, N., Tohda, A., Fukuoka, M., Nakagawa, K., 2002. Point mutations in the topoisomerase I gene in patients with non-small cell lung cancer treated with irinotecan. Lung Cancer 35, 299–304.
Ubezio, P., Tagliabue, G., Schechter, B., Agur, Z., 1994. Increasing 1-D-Arabinofuranosylcytosine efficacy by scheduled dosing intervals based on direct measurement of bone marrow cell kinetics. Cancer Res 54, 6446–6451.
Van Cutsem, E., Dicato, M., Wils, J., Cunningham, D., Diaz-Rubio, E., Glimelius, B., Haller, D., Johnston, P., Kerr, D.J. et al., 2002. Adjuvant treatment of colorectal cancer current expert opinion derived from the third international conference: perspectives in colorectal cancer, Dublin, 2001. Eur. J. Cancer 38, 1429–1436.
Webb, G., 1990. Resonance phenomena in cell population chemotherapy models. Rocky Mountain J. Math. 20, 1195–1216.
Webb, G., 1992a. A nonlinear cell population model of periodic chemotherapy treatment. In: Recent Trends in Ordinary Differential Equations. Series in Applicable Analysis. World Scientific Publishing Company, pp. 569–583.
Webb, G., 1992b. A cell population model of periodic chemotherapy treatment. In: Biomedical Modeling and Simulation. Elsevier Science Publishers, pp. 83–92.
Webb, G., Johnson, M., 1996. Resonances in age structured cell population models of periodic chemotherapy. Int. J. Appl. Sci. Comput. 3, 57–67.
Wheldon, T.E., 1988. Mathematical Models in Cancer Research. Adam Hilger Publishers, Bristol.
Wolfe, S.L., 1995. Introduction to Cell and Molecular Biology. Wadsworth.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Gaffney, E.A. The mathematical modelling of adjuvant chemotherapy scheduling: Incorporating the effects of protocol rest phases and pharmacokinetics. Bull. Math. Biol. 67, 563–611 (2005). https://doi.org/10.1016/j.bulm.2004.09.002
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1016/j.bulm.2004.09.002